English
Afrikaans
Albanian
Amharic
Arabic
Armenian
Azerbaijani
Basque
Belarusian
Bengali
Bosnian
Bulgarian
Catalan
Cebuano
Chichewa
Chinese (Simplified)
Chinese (Traditional)
Corsican
Croatian
Czech
Danish
Dutch
English
Esperanto
Estonian
Filipino
Finnish
French
Frisian
Galician
Georgian
German
Greek
Gujarati
Haitian Creole
Hausa
Hawaiian
Hebrew
Hindi
Hmong
Hungarian
Icelandic
Igbo
Indonesian
Irish
Italian
Japanese
Javanese
Kannada
Kazakh
Khmer
Korean
Kurdish (Kurmanji)
Kyrgyz
Lao
Latin
Latvian
Lithuanian
Luxembourgish
Macedonian
Malagasy
Malay
Malayalam
Maltese
Maori
Marathi
Mongolian
Myanmar (Burmese)
Nepali
Norwegian
Pashto
Persian
Polish
Portuguese
Punjabi
Romanian
Russian
Samoan
Scottish Gaelic
Serbian
Sesotho
Shona
Sindhi
Sinhala
Slovak
Slovenian
Somali
Spanish
Sudanese
Swahili
Swedish
Tajik
Tamil
Telugu
Thai
Turkish
Ukrainian
Urdu
Uzbek
Vietnamese
Welsh
Xhosa
Yiddish
Yoruba
Zulu
Telung studi anyar dening AS Pusat Pengendalian lan Pencegahan Penyakit (CDC) nuduhake manawa tembakan booster Pfizer-BioNTech lan Moderna 90% efektif kanggo nyegah wong metu saka rumah sakit sawise kena infeksi virus Omicron saka virus COVID-19.
Dosis booster wis kabukten efektif banget kanggo nyegah Omicronrumah sakit -related, miturut CDC.
Jab booster uga 82% efektif kanggo nyegah departemen darurat lan kunjungan perawatan darurat, data riset dituduhake.
Panaliten kasebut kalebu panaliten AS gedhe sing pertama kanggo ndeleng perlindungan vaksin Omicron, pejabat kesehatan ngandika.
"Wong Amerika kudu njaluk boosters yen paling ora limang sasi wis liwati wiwit rampung seri Pfizer utawa Moderna, nanging mayuta-yuta sing layak durung entuk," CDC's Emma Accorsi, salah siji saka penulis sinau ngandika.
Makalah kasebut nyuarakke riset sadurunge - kalebu pasinaon ing Jerman, Afrika Kidul lan Inggris - nuduhake vaksin sing kasedhiya kurang efektif nglawan Omicron tinimbang versi koronavirus sadurunge, nanging uga dosis booster nambah antibodi sing nglawan virus kanggo nambah kemungkinan ngindhari. infeksi simtomatik.
